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Summary
Objectives: Previous studies of patients with primary hand and ankle osteoarthritis (OA) have suggested the presence of two major polyar-
ticular OA (POA) phenotypes, designated Type 1 and Type 2. The former, characterised by sentinel distal interphalangeal (IP) (DIP) or prox-
imal IP (PIP) joint OA resembles generalised OA (GOA), whereas the latter characterised by sentinel metacarpophalangeal (MCP)2,3 OA,
resembles the arthropathy associated with hereditary haemochromatosis (HH). The aim of this study was to validate these putative pheno-
types and to further investigate their clinical and genetic characteristics.
Methods: Newly referred patients had X-rays if pre-determined clinical criteria for OA in hand and other joints were met. Subjects were as-
signed to the putative Type 1 POA (T1POA) or Type 2 POA (T2POA) phenotypes if radiological criteria were satisﬁed. Human haemochro-
matosis (HFE) gene mutations were determined in buffy-coat DNA by polymerase chain reaction ampliﬁcation, followed by restriction enzyme
cleavage and analysis on a 3% agarose gel. The signiﬁcance of differences was determined by Chi-square test or by Fisher’s exact test.
Results: Sixty-seven patients fulﬁlled criteria for inclusion in this study; 39 (6M, 33F) for T1POA and 28 (18M, 10F) for T2POA. A statistically
signiﬁcant difference in gender was observed (64% male in the T2POA subset, P< 0.0001). Heberden’s nodes (HNs) were found in 34 of the
39 Type 1 subjects, but in only nine of the 28 Type 2 subjects (P< 0.0001). HFE gene mutations were found in nine of the 39 Type 1 subjects
(23%), whereas 21 of the 28 Type 2 subjects had a single HFE gene mutation (75%, P< 0.0001).
Conclusions: These ﬁndings conﬁrm the hitherto hypothetical proposition of a T1POA phenotype conforming to nodal GOA (NGOA) and
a T2POA phenotype closely resembling the arthropathy described in haemochromatosis (HH).
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Abbreviations: POA Polyarticular osteoarthritis, HH Hereditary haemochromatosis, HNs Heberden’s nodes, HFE Human haemochromatosis
gene, C282Y Tyrosine substitution for cysteine at amino acid position 282 in the HFE protein, H63D Aspartic acid substitution for histidine at
amino acid position 63 in the HFE protein, NGOA Nodal generalised osteoarthritis, T1POA phenotype Type 1 polyarticular osteoarthritis phe-
notype, T2POA phenotype Type 2 polyarticular osteoarthritis phenotype, DIP joint Distal interphalangeal joint, PIP joint Proximal interphalan-
geal joint, MCP2,3 Index and middle ﬁnger metacarpophalangeal joints, STT joint Scaphoidetrapeziumetrapezoid joint, RC joint Radio-carpal
joint, TMT joint Tarso-metatarsal joint, MTP1 joint Great toe metatarsophalangeal joint, KL criteria Kellgren and Lawrence criteria.Osteoarthritis (OA) is the commonest disease of the joints.
It was estimated to affect 1.62 million Australians or 7.7% of
the total population of Australia in 20071. These rates are
similar to those reported elsewhere. Multiple joint involve-
ment or polyarticular OA (POA) is common. Kellgren and
Moore reported a form of POA designated generalised
OA (GOA) in 1952. Others including Lawrence, Spector
and Campion, Cooper et al. and Hirsch et al. have observed
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891notion of POA subsets2e6. Heberden’s nodes (HNs), which
are often observed in subjects with POA, which has led to
the proposition that these lesions may represent a clinical
marker for at least one form of POA7. Moreover, the fre-
quent ﬁnding of HNs in POA has given rise to the notion
of nodal GOA (NGOA)8.
In 2006 one of the authors (GC) postulated twomajor POA
phenotypes, one of which is characterised by sentinel inter-
phalangeal (IP) joint involvement conforming to theGOAsub-
set and the other, a hitherto unrecognised yet common POA
subset, characterised by sentinel OA in the index and/or mid-
dle ﬁnger metacarpophalangeal (MCP) (MCP2,3) joints,
closely resembling the arthropathy attributed to hereditary
haemochromatosis (HH)9e11. HH is a common disorder
Table I
Clinical criteria used to determine whether radiological examination
were indicated
Joint Clinical criteria to qualify for X-ray
RC Extension <45( or ﬂexion< 45(
Elbow Extension deﬁcit of 10( or more or ﬂexion< 120(
Hip Flexion< 100( or int. rot. <20(
Knee Extension deﬁcit of 10( or more or ﬂexion< 120(
Ankle Plantarﬂexion< 20(
TMTs Hard tissue swelling or palpable
osteophytes, pain with passive inversion
or eversion or tenderness with squeeze
compression of the TMT joints
MTP1 joints Hard tissue swelling or palpable osteophytes
or passive extension< 60(
892 G. J. Carroll et al.: Two major POA phenotypeswhich usually arises due to mutations in the HFE or human
haemochromatosis gene found on chromosome 6. The two
most common and only clinically relevant mutations in the
HFE gene are the C282Y and H63D mutations which are
found in one in seven and one in three Caucasians, respec-
tively (allele frequency one in 14 and one in six, respec-
tively)12. In an earlier study, a high frequency of HFE gene
mutations was noted in subjects with MCP2,3 POA (62%
were heterozygous for either C282Y or H63D) in contrast to
the IP joint OA group where the frequency of HFE gene mu-
tations was appreciably lower (18% heterozygous for either
C282Y or H63D), but similar to that in an ethnically and geo-
graphically comparable Western Australian population co-
hort12 derived from the Southwest town of Busselton.
In clinical practice it was observed that in subjects with
NGOA, knee joint OA, especially medial compartment
knee OA was common. Likewise in the same group OA
was often observed in the great toe MTP (MTP1) joint. Ac-
cordingly it was postulated that IP [multiple distal IP (DIP),
multiple proximal IP (PIP) or combinations of both] joint
POA accompanied by symmetrical OA in either both knee
(medial compartment) or both MTP1 joints may provide a ro-
bust deﬁnition for the NGOA or Type 1 POA (T1POA) phe-
notype. Furthermore, in light of the ﬁnding that subjects with
HH and arthropathy often exhibit OA in somewhat atypical
joints such as the radio-carpal (RC), elbow, ankle and
tarso-metatarsal (TMT) joints and since in these joints pre-
liminary data suggested higher than background population
frequencies of HFE gene mutations for most of these joint
groups12, it was hypothesised that involvement of one or
more of these atypical joints in addition to two or more of
the MCP2,3 joints may robustly deﬁne a second major
POA phenotype designated Type 2 POA or T2POA. More-
over, it was predicted that if indeed the T1POA and T2POA
subsets were phenotypically different, they would have
other deﬁning clinical characteristics and also potentially dif-
ferent genetic characteristics, including different frequen-
cies of HFE gene mutations. The existence of these two
hypothetical POA phenotypes was a pre-speciﬁed hypothe-
sis and that they would differ not only in terms of joint topog-
raphy, but also in respect to clinical and genetic
characteristics (HFE genotype) was also predicted. The
aim of this study was to test this hypothesis.Methods
The design and ethical implications of this project were reviewed and ap-
proved by the Ethics and Human Rights Committee of the South Metropoli-
tan Area Health Service in Perth, Western Australia. From 01/07/04 to 30/06/
07, newly referred subjects (n¼ 4749) with musculoskeletal symptoms were
screened for clinical evidence of POA by a single investigator (GC). All pa-
tients referred by rural and metropolitan community-based general practi-
tioners for clinical assessment were considered eligible for the study. No
patients were referred because haemochromatosis was suspected and no
new cases of haemochromatosis were identiﬁed during the study. Subjects
with co-existent arthropathies such as rheumatoid arthritis, ankylosing spon-
dylitis, psoriatic and enteropathic arthropathies, auto-immune connective tis-
sue diseases and crystal arthropathies were excluded. Clinical screening
criteria were used to identify patients with POA (Table I). Where the screen-
ing criteria for potential assignment to T1POA or T2POA on the basis of the
deﬁned joint topography were met, patients were invited to consent to X-rays
of the clinically abnormal joints and the collection of blood for iron studies and
HFE genotyping. X-rays were assessed by an experienced radiologist with
a special interest in musculoskeletal disorders and by a rheumatologist
with a special interest in OA. X-rays were assessed blind (without knowledge
of the clinical characteristics of the patients or the investigation results). The
joints under study (ﬁnger DIPs, thumb IPs, ﬁnger PIPs, ﬁnger and thumb
MCPs, carpometacarpal1(CMC1) joints and the scaphoidetrapeziumetrape-
zoid or STT joints and knee joints) were graded on a 0e4 scale by the ordinal
criteria of Kellgren and Lawrence (KL)14. For the RC, elbow, hip, ankle and
TMT joints, where no valid KL criteria are available, patients were required tohave either unequivocal osteophytes or unequivocal joint space narrowing.
Where there was a difference of 1 grade, the opinion of the radiologist
was accepted. Where there was a difference of 2 or more grades the differ-
ence was resolved by combined review of the radiographs and consensus
agreement. To assess the overall severity of POA, in the hand, the KL grade
for all of the joints speciﬁed was summed to produce a severity score. Sub-
jects who met screening criteria for clinical evidence of OA in pre-speciﬁed
joints other than those in the hands (see Table I) had X-rays of the involved
joints and the respective contralateral joint(s). Subjects were assigned to one
or other of the two POA subtypes if the following qualifying clinical and radio-
graphic criteria were met. Patients were assigned to the T1POA phenotype if
they had radiological evidence of OA in at least two DIP or PIP joints and in
either both knees (medial compartment) or both great toe MTP joints. Sub-
jects assigned to this phenotype were not permitted to have radiological ev-
idence of OA in any of the ﬁnger MCP joints. Patients were assigned to the
T2POA phenotype if they had radiological evidence of OA in at least two of
the four MCP2,3 joints and in at least one of the RC, elbow, hip, ankle, or
TMT joints. Other joint involvement such as in the PIP and/or DIP joints of
the same or other rays in the hand was permitted. Examples of the two
phenotypes are shown in Fig. 1. Serum iron, serum transferrin, calculated
transferrin saturation and serum ferritin were measured. No patient met the
pre-speciﬁed transferrin saturation exclusion criterion of greater than 48%.
HFE gene mutations were determined in buffy-coat DNA by polymerase
chain reaction (PCR) ampliﬁcation using published primers (12), followed
by restriction enzyme cleavage and analysis on a 3% agarose gel. Subjects
were assessed for C282Y using the unique RsaI digestion site. H63D was
determined using the unique MboI digestion site. Subjects were divided
into (1) wild types, (2) C282Y/wild-type heterozygotes, (3) compound
C282Y/H63D heterozygotes, (4) C282Y homozygotes and (5) H63D homo-
zygotes. Statistical evaluation was performed utilising unpaired two-tailed
Student’s t test for continuous data and for categorical data the signiﬁcance
of differences was determined by Chi-square test where the expected cell
frequency was greater than 5, otherwise by Fisher’s exact test. P val-
ues< 0.05 were considered to be statistically signiﬁcant.Results
Sixty-seven subjects met the pre-deﬁned clinical and radio-
graphic criteria for assignment to one or other subset. Thirty-
nine were assigned to the T1POA subset (33 F, 6M) and 28
to the T2POA subset (10F, 18M), as can be seen in Table II.
The ages of the subjects in these two respective subsets
were 66.6 8.6 yrs (meanSD) for T1POA and
70.6 8.4 yrs for T2POA (Table II). Although there was
a strong trend towards older subjects in the T2POA subset,
the difference was not statistically signiﬁcant (P¼ 0.0633). A
striking difference in gender ratio was observed (85% F in
T1POA compared to 36% F in T2POA, P< 0.0001, Table II).
This accordswith the predominance of females inNGOAas re-
ported by Kellgren andMoore2. The predominance of males in
the T2POA subset is similar to the male predominance ob-
served in the arthropathy which accompanies HH. The fre-
quency of HNs was appreciably higher in T1POA
(P< 0.0001, Table II). Moreover the mean number of HNs
per patient was signiﬁcantly higher in the T1POA subset
(P< 0.0001, Table II). Bodymass indiceswere not determined
Fig. 1. Examples of the T1POA and T2POA phenotypes.
Table II








Gender 6M/33F 18M/10F <0.0001
Age (meanSD) 66.6 (8.6) 70.6 (8.4) 0.0633 (NS)
Frequency of HNs 34 12 0.0002
Number of HNs
(meanSD)
4.92 (2.63) 1.86 (2.72) <0.0001
Serum ferritin mean
(SD in mcg/L)




2 (5.2) 4 (14.3) 0.2269
HFE gene mutations 9 21 <0.0001
893Osteoarthritis and Cartilage Vol. 17, No. 7for the subjects assigned to the two POA subsets. No differ-
ence in serum iron or transferrin saturation was observed, but
a trend towards higher serum ferritin concentrations was noted
in T2POA (157 125 for T2POA vs 119 90 for T1POA,
P¼ 0.1065, NS Table II). Two of the 39 (5.2%) in the T1POA
group had an elevated serum ferritin compared to four of the
28 (14.3%) in the T2POA group (not signiﬁcant, P¼ 0.2269,
Fisher’s exact test). A marked difference in the frequency of
HFE gene mutations was noted (Table II). For the purpose of
aggregate analysis, homozygotes for H63D were added to
compound heterozygotes and non-compound heterozygotes
for either C282Y or H63D. There was one H63D homozygote
and two H63D/C282Y compound heterozygotes in the
T1POA subset, whereas no H63D homozygotes or compound
heterozygoteswereobserved in theT2POAsubset.C282Yho-
mozygotes were not observed in either subset. Nine of the 39
T1POA subjects had at least one HFE gene mutation (23%)
compared to 21 of the 28 T2POA subjects (75%,
P< 0.0001). The ﬁndings in the T1POA subset are similar to
those observed in an ethnically and geographically age
matched population cohort from the town of Busselton inWest-
ern Australia where 38% of the sample population (n¼ 3011)
were either homozygous, heterozygous or compound hetero-
zygous for C282Y or H63D12. The frequency of HFE genemu-
tations in the T1POA subset was also very similar to that
observed for IP joint OA in our previous study (18%)13. The al-
lele frequency forH63Dwas found tobeone in20 for theType1
phenotype and one in four for the Type 2 phenotype whereas
the allele frequency for C282Y was found to be one in 40 for
the Type 1 phenotype and one in eight for the Type 2 pheno-
type. The strong association of HFE gene mutations with
T2POA is consistent with earlier observations in MCP2,3 OA
alone (62% of subjects had HFE gene mutations however
these patients were required to have only one or more of the
four MCP2,3 joints affected)13. This ﬁnding nevertheless rein-
forces the previous results13. In this study, the strength of the
association was numerically higher, but the two groups arenot strictly comparable, since toqualify forT2POA in thecurrent
study, subjects were required to have OA in more than one of
the four MCP2,3 joints and also in at least one other speciﬁed
joint. This more rigorous deﬁnition for the T2POA subset may
account for the difference. The frequency of other joint involve-
ment in the two subsets was compared for some joints which
were not pre-speciﬁed and where adequate data were fortu-
itously available (Table IV). A slightly higher frequency of
CMC1 OA was observed in T1POA and a slightly higher fre-
quency of STT OA in T2POA, but these differences were not
statistically signiﬁcant andascanbeseen fromTable III, the se-
verity scores for these joints differed minimally.
The overall severity of theOAas determined byKL grading
was compared for the two phenotypic subsets (Table III).
A trend towards more severe OA was observed in the
T2POA subset, due to the added contribution of the MCP
joints, there being a similar degree of OA in the other compo-
nent joint groups. The difference was not statistically signiﬁ-
cant. Ligamentous chondrocalcinosis was observed in two
Table IV
Frequency of joint involvement in the T1POA and T2POA OA phe-
894 G. J. Carroll et al.: Two major POA phenotypesof the 28 T2POA subjects. None of the T2POA or T1POA
subjects had chondrocalcinosis in the articular cartilage.notypes, frequency of chondrocalcinosis in ligaments and cartilage







CMC1 22 14 NS
STT 5 8 NS
RC 0 2* Inappropriate
Elbow 0 4* Inappropriate
Hip 6 7* Inappropriate
Knee 10* 11 Inappropriate
TMTs 2 7* Inappropriate
MTP1s 32* 15 Inappropriate
Chondrocalcinosis
(ligamentous)





score for 32 hand
joints, meanSD
22.7 (14.2) 31.4 (23.3) P¼ 0.1022 (NS)
*Denotes that this joint was a criterion for assignment to the
T1POA or T2POA category, respectively, and in these cases statis-
tical comparisons were deemed inappropriate due to selection bias.Discussion
This study was designed to validate earlier observations,
test new hypotheses and predictions and to reﬁne and inform
an evolving model of POA, which conceptualises at least two
major POA subsets or phenotypes, designated Type 1 POA
or T1POA and Type 2 POA or T2POA. The strengths and
weaknesses of this study require comment. The strengths
of the study include (1) theprospective recruitment ofOAsub-
jects referred from the community by family medicine physi-
cians or general practitioners, (2) the use of a single clinical
observer who consistently utilised pre-speciﬁed methods of
clinical assessment, (3) the veriﬁcation of OA by radiological
assessment and (4) the opportunity to capture data concern-
ingOA inother joints not pre-speciﬁedandnot readily amena-
ble to clinical evaluation. Weaknesses include (1) data
omissions due to design ﬂaws and oversights, in particular
the lack of data concerning occupation and the extent and du-
ration of hard manual labouring activity, (2) the absence of X-
ray data for joints which did not meet the strict clinical criteria
for X-ray examination and importantly, (3) the relatively small
number of patients, which in turn limits statistical power.
Clearly, the single geographic location limits generalisability
and in particular makes it difﬁcult to exclude a locally inﬂated
T2POA frequency, possibly due to a founder effect.
Nonetheless, the available data strongly support the like-
lihood that in Western Australian Caucasians, there are at
least two numerically frequent POA subsets, one of which
conforms closely to the putative generalised form of OA
or NGOA (proposed T1POA) and the other to a haemochro-
matosis e like arthropathy (proposed T2POA).
The role of occupational and biomechanical factors in the
development of OA in the MCP joints and in other joints in-
cluded in the putative T2POA phenotype also needs to be
considered. In a number of studies, OA in the MCP joints
and especially MCP1e3 has been found to be more fre-
quent in men involved in some form of hard manual labour-
ing work, such as agriculture15e17. OA in the hip joint is also
much more common in people involved in long-term farming
work18,19. It is postulated that on a particular genetic back-
ground, which may include mutations in the HFE gene or al-
ternatively other genes involved in the regulation of iron
metabolism, occupational/biomechanical factors may con-
tribute to the aetio-pathogenesis of the T2POA form of
OA. It would be interesting to examine whether there are dif-
ferences in the occupations of subjects with T1POA and
T2POA. It may also be informative to investigate whether
occupational factors contribute to the development and pat-
tern of arthropathy in HH and if these effects are similar to or
differ from those observed in the proposed T1POA and
T2POA phenotypes.Table III
Table depicting the summative KL grades for selected joint groups
and the significance of observed differences between the putative
T1POA and T2POA phenotypes
T1POA T2POA Signiﬁcance, P
DIPs 5.00 (6.15) 6.33 (6.85) 0.5100 (NS)
PIPs 9.45 (7.28) 7.47 (6.06) 0.3666 (NS)
PIPsþDIPs 14.45 (11.50) 13.80 (12.62) 0.8637 (NS)
MCPs 1.03 (1.54) 9.00 (6.57) <0.0001
CMC1s 2.65 (2.35) 3.50 (2.98) 0.3045 (NS)
STTs 1.23 (2.25) 1.57 (1.28) 0.5952The signiﬁcance of the observed strong association be-
tween HFE gene mutations and the T2POA phenotype is
unclear. Whether HFE mutations are just passenger gene
mutations, possibly in linkage dysequilibrium with other sin-
gle or multiple potentially more critical gene defects in
T2POA will require further study. Alternatively, the possibil-
ity that the HFE gene mutations themselves may be aetio-
logically/mechanistically important warrants consideration
and further investigation. A trend towards higher serum fer-
ritin concentrations, albeit still within the accepted normal
range, was observed in the T2POA subset, (Table II).
This may simply be due to the gender ratio, as higher serum
ferritin concentrations would be expected in the T2POA
subset since they are gender dependent (higher in males)
and there is a predominance of males in this group.
Whether the higher frequency of HFE gene mutations in
the T2POA subset is responsible for the trend towards
higher serum ferritin concentrations is unclear, but this
seems unlikely as signiﬁcantly higher serum ferritin concen-
trations have not been observed in people heterozygous for
HFE gene mutations in blood donor and other studies20,21.
It is possible that in T2POA, HFE gene mutations may pre-
dispose to a mild, but possibly important degree of localised
iron overload in the joints, which may in turn predispose to
chondral or other structural joint damage. Some support for
this possibility has been found in synovial ﬂuid studies. Our
preliminary data suggest that ferritin concentrations are in-
creased in synovial ﬂuid from OA subjects with HFE gene
mutations22. Yet another possibility is that people with
HFE gene mutations engaged in work or recreational activ-
ities that result in regular microtrauma and low grade bleed-
ing into the joint cavity, may be at increased risk for joint
damage. The observation that haemophiliacs who possess
HFE gene mutations develop more severe arthropathy
lends credence to this proposition23.
Alizadeh et al. have reported an association between
MCP arthropathy and homozygosity, but not heterozygosity
for H63D in a large suburban Dutch population cohort24.
None of our T2POA subjects was homozygous for H63D,
but it is possible that this HFE genotype confers an in-
creased risk for MCP2,3. OA and possibly also for the ex-
tended T2POA phenotype. It is of interest that in the
895Osteoarthritis and Cartilage Vol. 17, No. 7HEIRS study, male H63D homozygotes were reported to
have an increased risk for arthritis overall20. Further popula-
tion and other studies will be required to investigate whether
homozygosity for C282Y or H63D in the absence of sys-
temic iron overload are risk factors for OA in the MCP2,3
joints or for T2POA.
The similarity between the arthropathy observed in the
T2POA subjects and that found in HH is striking25e31. Our
observations in this and previous studies, taken together
with other published data31e33, raise the intriguing possibil-
ity that it may not be necessary to be homozygous, but
rather simply heterozygous for HFE gene mutations in order
to be at risk for the development of an arthropathy which is
topographically, clinically and radiologically very similar to
that observed in HH.
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